Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Jilin Aodong Makes $2 Million Initial Investment in Vital Therapies

publication date: Apr 7, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jilin Aodong Medicine Industry Group (吉林敖東藥業集團股份有限公) will make a small $2 million investment into Vital Therapies, a San Diego company that is developing a medical device for patients with liver failure. The initial $2 million investment will purchase a stake in Vital Therapies of between 5% and 6%. If Vital Therapies obtains SFDA approval for its device in the next six months, Aodong will invest an additional $25 million in Vital Therapies. More details....

Stock Symbol: (SHE: 000623)     Share this with colleagues:  



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors